2 Minute Read
The pharmaceutical industry faces increasing difficulty accurately calculating and reporting government prices due to stringent regulations and recent complex changes.
4 Minute Read
Independent pharmacies are struggling due to the Inflation Reduction Act (IRA), which increases drug costs and tightens payer restrictions, affecting their finances. The 340B program, meant to aid low-income...
2 Minute Read
Efficient inventory management is crucial for healthcare organizations to ensure patient satisfaction, maintain financial stability, and mitigate supply chain risks. Moving forward, drug manufacturers must adapt their inventory management...
4 Minute Read
As the industry approaches full compliance with DSCSA requirements, new challenges emerge, particularly in managing data discrepancies, addressing inventory exceptions, and navigating gross-to-net impacts.
2 Minute Read
Read the latest blog from our CCO Tim Murdoch, Why I Chose IntegriChain: A Journey from Tech Giants to Transforming Pharma Commercialization.
3 Minute Read
Read the latest on the CMS September Final Rule Overview & a Controversial 340B Rebate Policy
3 Minute Read
Katie Herrick and Dan Landis, consultants from Blue Fin Group, discuss how pharmaceutical companies are adapting to the changing healthcare environment by focusing on improving patient access and affordability.
4 Minute Read
Nick Lynch, Partner of Federal Compliance Solutions (FCS) discusses insights into recent developments in pharmaceutical pricing, focusing on government programs like 340B, Medicaid Drug Rebate Program (MDRP), Medicare Part...
6 Minute Read
Read the latest on Industry Updates, Biosimilar Barriers, and the Impact of Drug Price Negotiations.